Symbiotec Pharmalab IPO announced: ₹112.50 crore issue, what you need to know
Symbiotec Pharmalab files DRHP for IPO with ₹112.50 Cr fresh issue for debt repayment. Global leader in corticosteroid APIs with 38.20% market share. Revenue grew 10.16% CAGR to ₹869.15 Cr in FY2026. Risks include high API concentration and US FDA observations.
*this image is generated using AI for illustrative purposes only.
Symbiotec Pharmalab’s IPO closed with a colossal late-stage surge, ending at 71.19x overall subscription. Qualified Institutional Buyers (QIB) drove the momentum, jumping sharply in the final hours to reach 172.03x. The Non-Institutional Individual (NII) category remained robust, while Retail interest also ticked up significantly by close.
Final Subscription Status
The issue ended its final day with significant momentum from institutional investors who accelerated bids sharply after 2 PM. The Non-Institutional Individual (NII) category remained strong, with bHNI leading individual demand.
| Category | Subscription Multiple |
|---|---|
| QIB | 172.03x |
| NII (bHNI) | 82.92x |
| NII (sHNI) | 54.98x |
| Retail | 12.84x |
| Employees | 15.29x |
| Overall | 71.19x |
Subscription Progression
Demand accelerated sharply throughout the four-day window. While early days saw modest interest, Day 4 brought a decisive institutional push that lifted the total multiple significantly from 37.95x to 71.19x in the final session.
| Day | Date | QIB | NII (bHNI) | NII (sHNI) | Retail | Total |
|---|---|---|---|---|---|---|
| Day 1 | 24-08-2026 | 0.35x | 1.56x | 0.77x | 0.94x | 0.79x |
| Day 2 | 25-08-2026 | 0.54x | 4.03x | 2.42x | 2.08x | 1.83x |
| Day 3 | 26-08-2026 | 0.59x | 13.77x | 11.11x | 5.00x | 5.24x |
| Day 4 | 27-08-2026 | 172.03x | 82.92x | 54.98x | 12.84x | 71.19x |
Intra-day Timeline (27-08-2026)
The standout move occurred between 11:15 AM and 4:15 PM, where QIB subscription raced ahead, more than tripling again in the final hours to reach 172.03x. Total subscription jumped +676.3% today (from 9.17x to 71.19x).
| Time (IST) | QIB | NII (bHNI) | Retail | Total |
|---|---|---|---|---|
| 11:15 | 0.63x | 23.10x | 6.76x | 9.17x |
| 12:15 | 2.01x | 28.88x | 8.07x | 12.07x |
| 13:15 | 10.40x | 35.50x | 9.18x | 17.19x |
| 14:15 | 17.62x | 32.34x | 6.47x | 18.36x |
| 15:15 | 63.13x | 49.55x | 11.38x | 37.95x |
| 16:15 | 172.03x | 54.52x | 12.40x | 70.94x |
| 17:15 | 172.03x | 54.98x | 12.84x | 71.19x |
About the Company
Symbiotec Pharmalab Limited is a research and development-driven pharmaceutical and biotechnology company. It holds a global leadership position in corticosteroid and steroidal-hormone APIs, with a 38.2% global volume market share in corticosteroids. Founded in 2002, the company operates as a CDMO for specialty pharmaceutical companies globally.
Financial Highlights
The company reported consistent revenue growth over the last three fiscal years. Total equity increased significantly, reflecting retained earnings and capital efficiency.
| Particulars | FY 2026 (₹ crores) | FY 2025 (₹ crores) | FY 2024 (₹ crores) |
|---|---|---|---|
| Revenue from Operations | 869.15 | 751.55 | 716.25 |
| Total Profit (PAT) | 109.90 | 96.79 | 100.06 |
| Total Equity | 1149.59 | 814.71 | 714.84 |
Objects of the Issue
- Prepayment and/or repayment of outstanding borrowings: ₹112.50 crores
- General corporate purposes: Balance net proceeds
Risk Factors
- High Revenue Concentration in APIs: 96.07% of revenue derived from API sales in Fiscal 2026.
- Regulatory Compliance Risks: Manufacturing facilities subject to inspections; recent US FDA Form 483 observations noted.
- Significant Export Revenue Exposure: 67.04% of revenue from external customers outside India in Fiscal 2026.
What's Next
- Allotment Date: 2026-08-28
- Listing Date: 2026-09-01
- Basis of Allotment: Pro-rata basis expected given high subscription multiples in NII and Retail categories.
How might the recent US FDA Form 483 observations impact Symbiotec's ability to secure new contracts or maintain its premium pricing in the US market post-IPO?
Given the decline in the current ratio to 0.92, will the ₹112.50 Crore debt repayment be sufficient to restore short-term liquidity, or will further capital raising be necessary?
What is the company's strategy to mitigate the risk of high customer concentration, where the top ten clients account for over 57% of sales without long-term contracts?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
